FT Vest U.S. Equity Buffer ETF - May (FMAY)
Live price chart, market sentiment, and community perspectives for FT Vest U.S. Equity Buffer ETF - May (CBOE: FMAY).
Live price chart, market sentiment, and community perspectives for FT Vest U.S. Equity Buffer ETF - May (CBOE: FMAY).
On our desk, we are closely tracking FMAY's total net assets, which have climbed past $1.4B. This liquidity growth is a positive signal for institutional validation in the structured outcome category, though the 0.85% total expense ratio remains a drag we must account for in long-term models.
Watching the recent push to new 1-year highs near $55.94 to $57.05, market sentiment feels cautiously neutral. While the 10% downside buffer against the SPDR SandP 500 ETF Trust is attractive, the macro backdrop featuring sticky Fed rates between 4.25% and 4.50% and a forward P/E of 20-21x keeps our equity risk premium tightly constrained.
From a risk management protocol perspective, we emphasize to clients that FMAY's 10% buffer and 17.09% cap only function properly if the fund is held from the inception of the annual outcome period on May 18, 2026. Mid-period entries expose portfolios to unbuffered gaps if the SandP 500 corrects sharply.
From a portfolio construction standpoint, the 1-year price return of 14.93% looks solid in absolute terms, but we remind allocators that a defined outcome fund deliberately sacrifices full index participation for downside mitigation. The 50.84% cumulative 5-year return reflects this trade-off clearly.
Analyzing the quantitative profile, FMAY delivers a 5-year beta of 0.60 and a max drawdown of -13.0%, slightly beating the category median of -13.5%. However, its 5-year Sharpe ratio of 0.54 shows that compensation for risk matches peers precisely rather than outperforming them.
Reviewing technical indicators, FMAY is trading just 1.66% above its 200-day moving average near $52.29, leaving the fund in a neutral technical entry zone. Predictive AI models highlight elevated downside risk given that near-term sentiment is strong but lacks long-term support cushions beyond the fund's built-in structural buffer.
Explore plasma cleansing, somatic organ swaps, and BCI.